CellCentric
Biotech / oncology, Cambridge
Developing oral p300/CBP inhibitor inobrodib for multiple myeloma. It raised $220m in its Series D+ in May 2026. We can't read its job board yet.
Backed by Forbion and Sofinnova Partners.
Not found on the Home Office register of licensed visa sponsors.
Open roles over time
We can't read this company's job board yet.
Hiring momentum
Roles per weekNot tracked yet.
In the news
All 13 stories- FundingBusiness Weekly, 16 Sept 2026CellCentric wins Business of the Year at 36th Business Weekly Awards ahead of tipped US IPO
- FundingBioXconomy, 13 May 2026CellCentric potentially make a late-stage crawl towards IPO
- FundingFierce Biotech, 6 May 2026CellCentric raises $220M series D to advance myeloma drug through registration, eyes potential IPO
- Otherpharmaphorum, 6 May 2026CellCentric pockets $220m for blood cancer programme
- OtherBusiness Wire, 31 Mar 2026CellCentric Initiates DOMMINO-1, a Pivotal Phase 2 Clinical Trial of Inobrodib in Combination with Pomalidomide and Dexamethasone (InoPd) in Relapsed or Refractory Multiple Myeloma
- OtherBusiness Weekly, 2 Sept 2025CellCentric advances blood cancer trial